Abstracts tagged "Emmprin"

Abstract Number: 1246 • ACR Convergence 2021
The Effect of Tocilizumab on miR-146a-5p and EMMPRIN/CD147 in Rheumatoid Arthritis Patients
Devy Zisman¹, Mirna Safieh¹, Elina Simanovich¹, Joy Feld², Amalia Kinarty¹, Liron Zisman¹, Tal Gazitt³, Amir Haddad⁴, Muna Elias¹, Itzhak Rosner⁵, Lisa Kaly⁶ and Michal A Rahat⁷, ¹Carmel Medical Center, Haifa, Israel, ²Carmel and Zvulun Medical Centre, Haifa, Israel, ³Carmel Hospital, Haifa, Israel, ⁴Carmel Medical Centre, Haifa, Israel, ⁵Rheumatology Unit, Bnai Zion Medical Center, Haifa, Israel, ⁶Bnei Zion Medical Center, Haifa, Israel, ⁷Carmel Medical Center/Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel
Background/Purpose: Angiogenesis is an important contributor to the development of rheumatoid arthritis (RA). Tocilizumab (TCZ), an anti-IL-6 receptor antibody used in the treatment of RA…

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.

Abstracts tagged "Emmprin"

The Effect of Tocilizumab on miR-146a-5p and EMMPRIN/CD147 in Rheumatoid Arthritis Patients